SEARCH RESULTS

Pierre Fabre Dermocosmetic and Abbott Healthcare strengthen their partnership for the best French skincare range in India

Ridhima Verma - 05-mars-2015 08:06:37
    Pierre Fabre Dermocosmetic and Abbott Healthcare strengthen their partnership for the best French skincare range in India   ~ Avène Ducray & A-Derma products to re-define care for Indian skin ~ Mumbai, February 27, 2015: Pierre Fabre Dermo-cosmetic, 2nd largest dermo ‐ cosmetics laboratory in the World and Abbott Healthcare Pvt. Ltd., one of India’s largest pharmaceutical & healthcare companies have today announced the renewal of their partnership for commercialisation in India of 3 unique dermo-cosmetic ranges, namely AVÈNE, DUCRAY and A-DERMA .   AVÈNE products are formulated with the unique Avène Thermal Spring Water that runs in the South of France. They specialize in highly sensitive skincare, and are globally recommended for Sensitive, Atopic, Intolerant and Allergy prone skin. DUCRAY is the most medical brand existing on the dermo-cosmetic market and A-DERMA is exclusively formulated with Rhealba® oat cultivated organically in the South of France and offering unique soothing properties. This vast range of products covers Cleansing , Moisturizing , Anti-Ageing , Anti-Acne , Sun Protection , Hyper-pigmentation but also healing for atopic and sensitive skins. Pierre Fabre Dermo-cosmetic ranges promise to fulfil the needs of every skin type in India by offering variants for dry, normal and a combination skin.     “Abbott’s partnership with Pierre Fabre shows our commitment to bring to India globally renowned derma-cosmetic formulations.   Its AVÈNE, DUCRAY and A-DERMA globally popular brands addresses multitudes of skin concerns of people with sensitive skin or irritated skin; and preserving health and beauty of normal skin and hair,” said M. Sudarshan Jain, Managing Director of Abbott Healthcare.”     “Pierre Fabre’s background as a pharmaceutical company specializing in Dermatology in addition with its French know-how of cosmetic formulation is today perfectly completed with a high knowledge of the Indian market through our association with Abbott. In order to fulfil the highest expectations of sensitive or fragile skins, clinical and consumer tests have been performed internationally but also locally to show efficiency and acceptation of our formulations on Indian skin.”   Added M. Eric Ducournau, Chairman Pierre Fabre Dermo-Cosmetics.   Commenting on their plans in the Indian market , M. Pierre BEHNAM, Country Head Indian Operation said, “ The dermo-cosmetic market in India is fairly new but has a lot of potential. The current market size can be pegged at around 100 million Euros (700 Crores Roupies) within 5 years. We have plans to launch 6 new types of products per year and are therefore confident that our premium brands will be instrumental to convert this potential.. ”        T he entire range of Pierre Fabre Dermo-cosmetics products has been meticulously researched and developed to ensure they offer optimal solutions to today’s multiple skin needs particularly in India. Products are available at organized chemist stores across India.   About Pierre Fabre   Pierre Fabre is the 3rd largest French pharmaceutical group and the 2nd largest dermo-cosmetics laboratory in the world. In 2013, its sales reached €2.111 Billion, with Dermo-Cosmetics revenues accounting for 55% and international for 56%. Founded and its headquarters still based in the South-west of France, Pierre Fabre currently has branches in 44 countries and distribution agreements in over 130 countries.   Covering a continuum of healthcare products, from prescription drugs and consumer health care products (OTC, oral care, natural health) to dermo-cosmetics, Pierre Fabre Laboratories employ over 10,000 people worldwide. In 2013, Pierre Fabre allocated more than 17% of its drug revenues to R&D.   With brands such as Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Naturactive, Elgydium, Eludril or Drill, Pierre Fabre Laboratories are market leaders when it comes to skin, hair and oral care products distributed in the French pharmacy channel. Avène Thermal Spring Water is marketed worldwide, and is the leading dermo-cosmetics brand sold in Europe, Japan and China. In oncology, Pierre Fabre achieves 90% of its revenues outside of its home country.   Through the Pierre Fabre Participations holding company, the Pierre Fabre Foundation, a government-recognized public-interest foundation, owns 86% of Pierre Fabre Laboratories. Remaining shares are owned by company employees, amounting to 7%, and through treasury stock.   The French certification group AFNOR has audited Pierre Fabre Laboratories for its corporate social responsibility (CSR) performance at advanced level (AFAQ 26 000)   To find out more, please visit www.pierre-fabre.com       About Abbott:   Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 77,000 people.   In India, Abbott has more than 14,000 employees working in manufacturing, research and development, logistics, sales and marketing and is headquartered in Mumbai.   Visit Abbott at   www.abbott.com   and connect with us on Twitter at @AbbottNews .   For media enquiries, please contact:     Pierre Fabre Liaison Office P2 Percept House, 3d Floor Raghuvanshi Mills Compound 11/12 Senapati Bapat Marg, 400 013 Mumbai - India E-MAIL : pierre.behnam@pierre-fabre.com    

Biotechnology in France

Anindita BANERJEE - 08-avr.-2014 12:23:15
  Even though biotechnologies may be a recent sector of business activity, France has succeeded in developing real know-how that is gaining international recognition. When it comes to biotechnologies, the French are cutting edge. According to Leeme, the federation of French medical companies, today France numbers 388 biotechs in the health field in France. Biotech France, another French association for biotech companies, indicates that a third of these companies have been in existence for over 10 years. Yet the number of creations in this field is exponential. To get an idea, 50 companies were started in 2012. Unheard of! Proof that there is a real entrepreneurial effervescence when it comes to this research in France. Young start-ups for the most part, French biotechs are mainly Small Medium sized companies. Only 4% of them have over 100 employees. On average, they employ 22 people. As to the type of activity, most of the French companies specialized in human sciences with therapeutic products are concentrated on cancer treatments. “The French have developed a full-fledged know-how on cardio-vascular devices, infectious diseases, dermatology, blood diseases and for surgery,” explains Yves Germani, Ubifrance’s manager for the health sector in North America. French enterprises don’t just do research; they discover! Altogether, the French biotech industry generated 261 Million Euros in turnover in 2011, compared with 186 Million in 2010. As for companies on the stock market, they generate 369 Million Euros in turnover. Concerning the pipeline, the expression used to indicate the number of molecules being developed, France is 4rth, behind the United Kingdom, Germany, Switzerland and Israel. Quite a solid ranking, but which should nevertheless be improved. When their results are examined in detail, we see that depending on the stage of development, French companies create more products in the pre-clinic phase, in other words, all those that have been carried out before the clinical trial with patients, which is completely logical. Between the start of development on a new medicine, a molecule and its release on the market can sometimes take up to 10 years. Unfortunately, the consequence of this is that a number of products fall by the wayside. To be noted, however, is one undeniable fact: since 2008, French companies have sold more and more products. To put it another way, as Yves Germani points out, French companies don’t just do research; they discover!” An increase of 63% in investment Even more impressive than all the rest, French biotech companies tend to have smaller R&D budgets than their European and international competitors. Fortunately, the culture of venture capital is developing very quickly in this sector. To give the general picture, the funds raised by French biotechs have increased by 63,1% from 2009 to 2012, reaching 178 Million Euros. Since the year 2000, they have managed to raise 2.920 Billion Euros. Today, French companies are naturally turning towards international opportunities to find new partners and new financial leverage. The proof is that such Small Medium companies as Affilogic, MedinCell, Interactive Biosoftware, Imabiotech or even O4CP all have one thing in common: they all are reaching out with confidence to mature markets like the United States, Canada and Western Europe.  
About
Sophie Clavelier, Country Head   Welcome to the French Trade Commission Business France in India!     Our key mission is to promote trade relations between France and India. We assist French- based companies seeking potential partners and new markets in India, while helping Indian businesses to identify potential French suppliers, commercial and technical partners.   In India, our 4 offices are located in business hubs, New Delhi, Mumbai, Bengaluru and Chennai. We have a dedicated multicultural team of 38 experts in the following growing sectors: Agrofood Industry Industry and Cleantech Lifestyle and Healthcare Tech & Services Our Trade Commission also has a Press office in charge of helping French companies to communicate in India as well as a Market Access Department enabling them to better understand and adjust to the Indian regulatory and fiscal framework. In

READ MORE

Facebook
Press area & Media Gallery
List of last comments

Bluestorage is a subsidiary of the Bollo...

Malcolm MESSIER | février 22, 2019

AdBGQi Thank you for this impressive rep...

best pron | janvier 29, 2018

pYktcT Well I definitely liked studying ...

just another | novembre 08, 2017

dv1KAR Say, you got a nice post.Thanks A...

best pron | septembre 20, 2017